@article{JTD18491,
author = {Mark Niglas and Patrick Cheung},
title = {Ablative therapy in oligometastatic non-small cell lung cancer—an editorial on recent evidence},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {1},
year = {2018},
keywords = {},
abstract = {Lung cancer is the leading cause of cancer-related mortality, and will account for 26% of all cancer deaths in 2017 (1). With approximately 40% of all patients diagnosed with non-small cell lung cancer (NSCLC) presenting with stage IV disease (2), the optimal management of metastatic disease is an important question. In patients with oligometastatic NSCLC, often defined as 1 to 3 or 1 to 5 sites of metastatic spread, there is significant controversy in treatment approach (3).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/18491}
}